BlackRock Inc. trimmed its stake in Calithera Biosciences Inc (NASDAQ:CALA) by 9.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,050,175 shares of the biotechnology company’s stock after selling 300,750 shares during the period. BlackRock Inc. owned 8.00% of Calithera Biosciences worth $12,232,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Alps Advisors Inc. increased its position in Calithera Biosciences by 38.4% during the fourth quarter. Alps Advisors Inc. now owns 88,112 shares of the biotechnology company’s stock worth $353,000 after acquiring an additional 24,428 shares during the period. Rhumbline Advisers increased its position in Calithera Biosciences by 42.9% during the fourth quarter. Rhumbline Advisers now owns 45,332 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 13,612 shares during the period. Meeder Asset Management Inc. increased its position in Calithera Biosciences by 854.3% during the fourth quarter. Meeder Asset Management Inc. now owns 9,438 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 8,449 shares during the period. Virtu Financial LLC bought a new position in Calithera Biosciences during the fourth quarter worth about $49,000. Finally, Vanguard Group Inc increased its position in Calithera Biosciences by 5.4% during the third quarter. Vanguard Group Inc now owns 1,291,646 shares of the biotechnology company’s stock worth $6,781,000 after acquiring an additional 65,934 shares during the period. 55.48% of the stock is owned by hedge funds and other institutional investors.
Separately, ValuEngine raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, March 15th.
NASDAQ:CALA opened at $6.16 on Friday. Calithera Biosciences Inc has a 52 week low of $3.55 and a 52 week high of $7.45. The stock has a market cap of $241.20 million, a P/E ratio of -4.13 and a beta of 2.31.
Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.03). On average, analysts anticipate that Calithera Biosciences Inc will post -1.82 EPS for the current year.
Calithera Biosciences Profile
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
See Also: Gap Up Stocks
Want to see what other hedge funds are holding CALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calithera Biosciences Inc (NASDAQ:CALA).
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.